The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study

Basit Öğe Kaydı
dc.contributor.authorBeypinar, Ismail
dc.contributor.authorDemir, Hacer
dc.contributor.authorSakin, Abdullah
dc.contributor.authorTaskoylu, Burcu Yapar
dc.contributor.authorSakalar, Teoman
dc.contributor.authorErgun, Yakup
dc.contributor.authorKorkmaz, Mustafa
dc.date.accessioned2024-02-23T13:59:45Z
dc.date.available2024-02-23T13:59:45Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractPurpose Colorectal cancer is the third leading diagnosis accounting for nearly 10% of all new cancers worldwide. The distinct features among BRAF mutant colorectal cancers make these tumor groups hard to treat for oncologists. The median overall survival (OS) of these types of cancers is reported to be 9 to 14 months. Methods The study was declared on the Turkish Oncology Study Group Conference and approved. The patients' data was received from the centers who confirmed to participate. The BRAF-mutated patients were included in the study. The demographic features (age, gender, etc.), type of mutation, tumor localizations, histology, microsatellite instability (MSI) status, metastasis patterns chemotherapeutic agents and progression, and death times were recorded. Results Thirty-nine patients were enrolled in the study. Sixteen patients had concurrent KRAS mutations, while 7 had NRAS mutations. Most of the patients received doublet chemotherapies in combination with anti-VEGF agents in the first and second line of the treatment. There was a significant difference in OS according to the stage which showed a decreased survival in stage IV patients at the time of diagnosis. Concurrent KRAS mutation resulted in increased OS. The median OS was 47 and 24 months favoring the KRAS mutant group. The patients whose primary tumor operated had better survival when compared with other patients. The median OS of the operated group was 47 months, while the non-operated group was 24 months. Liver metastasis was related to worse prognosis at the time of diagnosis in univariate analysis. Conclusion In our study we found a high concurrent RAS mutation ratio in a BRAF mutant patient group which was different from prior studies. The concurrent mutations resulted in a favorable outcome in terms of OS which is also different from the current knowledge. More prospective studies are needed especially BRAF-mutated patient population and especially with concurrent RAS mutations.en_US
dc.identifier.doi10.1007/s12029-020-00514-9
dc.identifier.endpage939en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue3en_US
dc.identifier.pmid32914373en_US
dc.identifier.scopus2-s2.0-85090794027en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage932en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-020-00514-9
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11313
dc.identifier.volume52en_US
dc.identifier.wosWOS:000568135200002en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectColon Canceren_US
dc.subjectBrafen_US
dc.subjectKrasen_US
dc.subjectConcurrent Mutationen_US
dc.subjectReal-Life Experienceen_US
dc.titleThe Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu